Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 501

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 501
---
. In October 2022, TuHURA applied for a credit under this program and in May 2023, TuHURA received notice that the credit would be $0.3 million of which $0.1 million was received in 2024.

Grant Income.Grant income was $0.1 million and less than $0.1 million for the years ended December 31, 2024 and 2023, respectively. In April 2021, TuHURA received approval from the Department of Health and Human Services for a $0.4 million grant to study cervical cancer and received reimbursements for related expenses associated with the grant. TuHURA received the final payment under this grant in May 2023. Additionally, in October 2024, TuHURA assumed the Kintara Health and Human Services grant on REM-001 and received reimbursements for related expenses associated with the grant.

Interest Expense.From December 2023 to September 2024, as part of TuHURA’s private placement financing under which TuHURA offered and sold convertible promissory note (the “TuHURA Notes”), TuHURA issued convertible notes totaling $31,253,000. The convertible notes included interest at 20% per annum, accretion to maturity date, and amortization of debt discount. Upon the completion of the Kintara Merger, all principal and accrued and unpaid interest and make-whole amounts under the TuHURA Notes automatically converted into shares of TuHURA Common Stock at a conversion price $3.80 per share of TuHURA Common Stock. There was no cash paid for interest in the TuHURA Notes.

Interest Income.For the years ended December 31, 2024 and 2023, interest income was earned on deposits at various banks.

Change in fair value of derivative liability.For the year ended December 31, 2024, there was a loss of $0.3 million associated with the bifurcated embedded derivative liability related to the make-whole premium on the TuHURA Notes.

Preferred Stock Series A cash dividend.The holder of TuHURA’s Series A Preferred Stock received dividends payable quarterly in arrears, at an annual rate of 3% of the Series A Stated Value.

Warrant modification.For the year ended December 31, 2024, there was a $1.0 million deemed dividend due to extending the exercise period on certain of the Series A Warrants for an additional six months.

Liquidity and